PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY ADULT MALE SUBJECTS

被引：0
|
作者：
Gillen, M. [1 ]
Shen, Z. [2 ]
Miner, J. N. [2 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Ardea Biosci Inc, San Diego, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5133
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0886
引用
收藏
页码：1366 / 1366
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
    Christopher, Ronald
    Covington, Paul
    Davenport, Michael
    Fleck, Penny
    Mekki, Qais A.
    Wann, Elisabeth R.
    Karim, Aziz
    CLINICAL THERAPEUTICS, 2008, 30 (03) : 513 - 527
  • [22] Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during multiple rising dose regimens in healthy male subjects
    Rocha, J. -F.
    Nunes, T.
    Vaz-da-Silva, M.
    Machado, R.
    Wright, L.
    Falcao, A.
    Almeida, L.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 696 - 696
  • [23] Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
    Zhang, Libo
    Zhang, Weilong
    Xu, Yufeng
    Dong, Lihou
    Sun, Yunjuan
    Jia, Yingmin
    Li, Zhichuan
    Chen, Bo
    Hou, Jie
    Zhang, Jianzhong
    ADVANCES IN THERAPY, 2024, : 2953 - 2965
  • [24] Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Ford, John
    Lawson, Matt
    Fowler, David
    Maruyama, Nobuko
    Mito, Seiji
    Tomiyasu, Koichi
    Kinoshita, Shuji
    Suzuki, Chisa
    Kawaguchi, Atsuhiro
    Round, Patrick
    Boyce, Malcolm
    Warrington, Steve
    Weber, Werner
    van Deventer, Sander
    Kastelein, John J. P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) : 498 - 508
  • [25] Pharmacokinetics, pharmacodynamics and tolerability of oral cromolyn sodium/SNAC capsules in healthy and allergic male subjects
    Kremer, IB
    Abbas, R
    Arbit, E
    Van Lier, JJ
    Sollie, FAE
    Willemsen, MJJF
    Oosterhuis, B
    Van Vliet, AA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (04) : 467 - 468
  • [26] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
    Yoon, Seonghae
    Shin, Donghoon
    Lee, Howard
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5033 - 5049
  • [27] PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF LC350189, A NOVEL XANTHINE OXIDASE INHIBITOR, IN HEALTHY SUBJECTS
    Yoon, S.
    Moon, S.
    Jang, K.
    Jang, I.
    Lim, K.
    Yu, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S94 - S94
  • [28] Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    Almeida, Luis
    Rocha, Jose Francisco
    Falca, Amilcar
    Nuno Palma, P.
    Loureiro, Ana I.
    Pinto, Roberto
    Bonifacio, Maria Joao
    Wright, Lyndon C.
    Nunes, Teresa
    Soares-da-Silva, Patricio
    CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 139 - 151
  • [29] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
    Okui, Daisuke
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 92 - 102
  • [30] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
    Daisuke Okui
    Tomomitsu Sasaki
    Masahiko Fushimi
    Tetsuo Ohashi
    Clinical and Experimental Nephrology, 2020, 24 : 92 - 102
12345